Results 41 to 50 of about 171 (101)

Clindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically ill patients with bacteremic Group A Streptococcal infections. [PDF]

open access: yesRev Esp Quimioter, 2022
Fernández-Galilea A   +9 more
europepmc   +1 more source

Machine-learning-derived predictive score for early estimation of COVID-19 mortality risk in hospitalized patients. [PDF]

open access: yesPLoS One, 2022
González-Cebrián A   +10 more
europepmc   +1 more source

On the Valorization of Arbutus unedo L. Pomace: Polyphenol Extraction and Development of Novel Functional Cookies. [PDF]

open access: yesFoods, 2023
Duarte H   +8 more
europepmc   +1 more source

Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain. [PDF]

open access: yesOpen Respir Arch, 2023
Casas-Maldonado F   +7 more
europepmc   +1 more source

Social inequalities in multimorbidity patterns in Europe: A multilevel latent class analysis using the European Social Survey (ESS). [PDF]

open access: yesSSM Popul Health, 2022
Álvarez-Gálvez J   +8 more
europepmc   +1 more source

[Superficial venous thrombosis as the main clinical manifestation of SARS-COV-2 infection]. [PDF]

open access: yesSemergen, 2021
Rodríguez Adame C   +4 more
europepmc   +1 more source

Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study. [PDF]

open access: yesNeurol Ther, 2023
Meca-Lallana JE   +47 more
europepmc   +1 more source

Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units. [PDF]

open access: yesArch Bronconeumol, 2022
Torres A   +71 more
europepmc   +1 more source

[Optimizing blood pressure control through telemedicine in Primary Care in Spain (Iniciativa Óptima): Results from a Delphi study]. [PDF]

open access: yesAten Primaria, 2022
Sánchez Peinador C   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy